Therapeutic potential of TGF-β inhibition in chronic renal failure

Bibliography

• SCHIEPPATI A, PISONI R, REMUZZI G: Pathophysiology and management of chronic kidney disease. In: Primer on Kidney Diseases. Greenberg A, Cheung AK (Eds), WB Saunders Co., PA, USA (2005):444-454.
   Google Scholar
• XUE JL, MA JZ, LOUIS TA et al.: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol. (2001) 12:2753-2758.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, WEENING JJ: Albuminuria as early test for vascular disease. Lancet (2005) 365:556-557.
   PubMed Web of Science ®Google Scholar
• LYSAGHT MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol. (2002) 13(Suppl. 1):S37-S40.
   PubMed Web of Science ®Google Scholar
• GRIDELLI B, REMUZZI G: Strategies for making more organs available for transplantation. N. Engl. J. Med. (2000) 343:404-410.
   PubMed Web of Science ®Google Scholar
• ANDO T, OKUDA S, YANAGIDA T et al.: Localization of TGF-β and its receptors in the kidney. Miner. Electrolyte Metab. (1998) 24:149-153.
   Google Scholar
• WILSON HM, MINTO AW, BROWN PA et al.: Transforming growth factor-β isoforms and glomerular injury in nephrotoxic nephritis. Kidney Int. (2000) 57:2434-2444.
   PubMed Web of Science ®Google Scholar
• BLOBE GC, SCHIEMANN WP, LODISH HF: Role of transforming growth factor β in human disease. N. Engl. J. Med. (2000) 342:1350-1358.
   PubMed Web of Science ®Google Scholar
• PHANISH MK, WAHAB NA, COLVILLE-NASH P et al.: The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFβ1 responses in human proximal-tubule epithelial cells. Biochem. J. (2006) 393:601-607.
   PubMed Web of Science ®Google Scholar
• WANG W, HUANG XR, LI AG et al.: Signaling mechanism of TGF-β1 in prevention of renal inflammation: role of Smad7. J. Am. Soc. Nephrol. (2005) 16:1371-1383.
   PubMed Web of Science ®Google Scholar
• MALLICK NP, SHORT CD, HUNT LP: How far since Ellis? The Manchester Study of glomerular disease. Nephron (1987) 46:113-124.
   PubMedGoogle Scholar
• BERTANI T, CUTILLO F, ZOJA C et al.: Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int. (1986) 30:488-496.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. (1990) 38:384-394.
   PubMed Web of Science ®Google Scholar
• ZOJA C, BENIGNI A, REMUZZI G: Cellular responses to protein overload: key event in renal disease progression. Curr. Opin. Nephrol. Hypertens. (2004) 13:31-37.
   Web of Science ®Google Scholar
• WOLF G, SCHROEDER R, ZIYADEH FN et al.: Albumin up-regulates the Type II transforming growth factor-β receptor in cultured proximal tubular cells. Kidney Int. (2004) 66:1849-1858.
   PubMed Web of Science ®Google Scholar
• LIU HC, LIAO TN, LEE TC et al.: Albumin induces cellular fibrosis by upregulating transforming growth factor-β ligand and its receptors in renal distal tubule cells. J. Cell. Biochem. (2006) 97:956-968.
   PubMed Web of Science ®Google Scholar
• ABBATE M, ZOJA C, MORIGI M et al.: Trasforming growth factor-β1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins. Am. J. Pathol. (2002) 161:2179-2193.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, FUJIWARA Y, UEDA N et al.: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-b or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. (1993) 92:2597-2601.
   Google Scholar
• ROBERTS AB, SPORN MB: The transforming growth factor-βs. In: Peptide Growth Factors and Their Receptors. Sporn MB (Ed), Springer, Berlin, Germany (1990):419-472.
   Google Scholar
• BRUIJN JA, ROOS A, DE GEUS B, DE HEER E: Transforming growth factor-β and the glomerular extracellular matrix in renal pathology. J. Lab. Clin. Med. (1994) 123:34-47.
   Google Scholar
• TOMOOKA S, BORDER WA, MARSHALL BC et al.: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. (1992) 42:1462-1469.
   PubMed Web of Science ®Google Scholar
• HUWILER A, PFEILSCHIFTER J: Transforming growth factor β2 stimulates acute and chronic activation of the mitogen-activated protein kinase cascade in rat renal mesangial cells. FEBS Lett. (1994) 354:255-258.
   PubMed Web of Science ®Google Scholar
• WU DT, BITZER M, JU W et al.: TGF-β concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J. Am. Soc. Nephrol. (2005) 16:3211-3221.
   PubMed Web of Science ®Google Scholar
• OKADO T, TERADA Y, TANAKA H et al.: Smad7 mediates transforming growth factor-β-induced apoptosis in mesangial cells. Kidney Int. (2002) 62:1178-1186.
   PubMed Web of Science ®Google Scholar
• DAI C, YANG J, LIU Y: Transforming growth factor-β1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J. Biol. Chem. (2003) 278:12537-12545.
   PubMed Web of Science ®Google Scholar
• NANGAKU M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. (2006) 17:17-25.
   PubMed Web of Science ®Google Scholar
• MCMAHON S, GRONDIN F, MCDONALD PP et al.: Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J. Biol. Chem. (2005) 280:6561-6569.
   PubMed Web of Science ®Google Scholar
• KITAMURA M, SUTO TS: TGF-β and glomerulonephritis: anti-inflammatory versus prosclerotic actions. Nephrol. Dial. Transplant. (1997) 12:669-679.
   PubMed Web of Science ®Google Scholar
• JONES CL, BUCH S, POST M et al.: Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am. J. Pathol. (1992) 141:1381-1396.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, EBIHARA I, FUKUI M et al.: Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin. Immunol. Immunopathol. (1993) 66:33-42.
   PubMedGoogle Scholar
• MA LJ, JHA S, LING H et al.: Divergent effects of low versus high dose anti-TGF-β antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int. (2004) 65:106-115.
   PubMed Web of Science ®Google Scholar
• ABBATE M, ZOJA C, ROTTOLI D et al.: Proximal tubular cells promote fibrogenesis by TGF-β1-mediated induction of peritubular myofibroblasts. Kidney Int. (2002) 61:2066-2077.
   PubMed Web of Science ®Google Scholar
• DESMOULIÈRE A, GEINOZ A, GABBIANI F et al.: Transforming growth factor-β1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. (1993) 122:103-111.
   PubMed Web of Science ®Google Scholar
• OKADA H, DANOFF TM, KALLURI R et al.: Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. (1997) 273:F563-F574.
   PubMed Web of Science ®Google Scholar
• ZOJA C, CORNA D, BRUZZI I et al.: Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp. Nephrol. (1996) 4:213-221.
   PubMedGoogle Scholar
• ZOJA C, CORNA D, CAMOZZI D et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J. Am. Soc. Nephrol. (2002) 13:2898-2908.
   PubMed Web of Science ®Google Scholar
• BOLLINENI JS, REDDI AS: Transforming growth factor-β1 enhances glomerular collagen synthesis in diabetic rats. Diabetes (1993) 42:1673-1677.
   PubMed Web of Science ®Google Scholar
• ERMAN A, VEKSLER S, GAFTER U et al.: Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. J. Renin Angiotensin Aldosterone Syst. (2004) 5:146-151.
   PubMed Web of Science ®Google Scholar
• GILBERT RE, COX A, WU LL et al.: Expression of transforming growth factor-β1 and Type IV collagen in the renal tubulointerstitium in experimental diabetes. Diabetes (1998) 47:414-422.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, ZOJA C, CORNA D et al.: Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. (2003) 14:1816-1824.
   PubMed Web of Science ®Google Scholar
• SHANKLAND SJ, SCHOLEY JW, LY H et al.: Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int. (1994) 46:430-442.
   PubMed Web of Science ®Google Scholar
• HILL C, LOGAN A, SMITH C et al.: Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor β receptor expression in experimental diabetes in rats. Diabetologia (2001) 44:495-500.
   PubMed Web of Science ®Google Scholar
• RISER BL, DENICHILO M, CORTES P et al.: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. (2000) 11:25-38.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-ALBARRAN O, GOMEZ O, RUIZ E et al.: Role of systolic blood pressure on the progression of kidney damage in an experimental model of Type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). Am. J. Hypertens. (2003) 16:979-985.
   Web of Science ®Google Scholar
• SHINOMIYA K, FUKUNAGA M, KIYOMOTO H et al.: A role of oxidative stress-generated eicosanoid in the progression of arteriosclerosis in Type 2 diabetes mellitus model rats. Hypertens. Res. (2002) 25:91-98.
   PubMed Web of Science ®Google Scholar
• RISER BL, LADSON-WOFFORD S, SHARBA A et al.: TGF-β receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int. (1999) 56:428-439.
   PubMed Web of Science ®Google Scholar
• KAGAMI S, BORDER WA, MILLER DE et al.: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. (1994) 93:2431-2437.
   PubMed Web of Science ®Google Scholar
• ZIYADEH FN, SHARMA K, ERICKSEN M et al.: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J. Clin. Invest. (1994) 93:536-542.
   PubMed Web of Science ®Google Scholar
• ROCCO MV, CHEN Y, GOLDFARB S et al.: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int. (1992) 41:107-114.
   PubMed Web of Science ®Google Scholar
• ZIYADEH FN, HAN DC, COHEN JA et al.: Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-β system. Kidney Int. (1998) 53:631-638.
   PubMed Web of Science ®Google Scholar
• YANG CW, VLASSARA H, PETEN EP et al.: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc. Natl. Acad. Sci. USA (1994) 91:9436-9440.
   Google Scholar
• ZHOU G, LI C, CAI L: Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am. J. Pathol. (2004) 165:2033-2043.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, NAKAMURA T, NOBLE NA et al.: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA (1993) 90:1814-1818.
   PubMed Web of Science ®Google Scholar
• BREZNICEANU ML, WEI CC, ZHANG SL et al.: Transforming growth factor-β1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int. (2006) 69:1977-1985.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, NOBLE NA, COHEN AH et al.: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int. (1996) 49:461-469.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA K, TAKEMURA T, MURAKAMI K et al.: Transforming growth factor-β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab. Invest. (1993) 68:154-163.
   Google Scholar
• KIM JH, KIM BK, MOON KC et al.: Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. (2003) 64:1715-1721.
   PubMed Web of Science ®Google Scholar
• DE MURO P, FAEDDA R, FRESU P et al.: Urinary transforming growth factor-β1 in various types of nephropathy. Pharmacol. Res. (2004) 49:293-298.
   Google Scholar
• CHAN RW, LAI FM, LI EK et al.: Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. (2004) 50:2882-2890.
   PubMed Web of Science ®Google Scholar
• YANG Y, HOU Y, WANG CL et al.: Renal expression of epidermal growth factor and transforming growth factor-β1 in children with congenital hydronephrosis. Urology (2006) 67:817-821; discussion 821-812.
   PubMed Web of Science ®Google Scholar
• VURUSKAN H, CALISKAN Z, KORDAN Y et al.: Elevated plasma concentrations of transforming growth factor-β1 in patients with unilateral ureteral obstruction. Urol. Res. (2005) 33:465-469.
   PubMed Web of Science ®Google Scholar
• PFEIFFER A, MIDDELBERG-BISPING K, DREWES C et al.: Elevated plasma levels of transforming growth factor-β1 in NIDDM. Diabetes Care (1996) 19:1113-1117.
   PubMed Web of Science ®Google Scholar
• SATO H, IWANO M, AKAI Y et al.: Increased excretion of urinary transforming growth factor β1 in patients with diabetic nephropathy. Am. J. Nephrol. (1998) 18:490-494.
   PubMed Web of Science ®Google Scholar
• FAGERUDD JA, GROOP PH, HONKANEN E et al.: Urinary excretion of TGF-β1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients. Kidney Int. Suppl. (1997) 63:S195-S197.
   PubMedGoogle Scholar
• CHA DR, KIM IS, KANG YS et al.: Urinary concentration of transforming growth factor-β-inducible gene-h3(β ig-h3) in patients with Type 2 diabetes mellitus. Diabet. Med. (2005) 22:14-20.
   PubMedGoogle Scholar
• BORDER WA, NOBLE NA, JAMAMOTO T et al.: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (1992) 360:361-364.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, AKAGI Y, ANDO Y et al.: Gene therapy by transforming growth factor-β receptor-IgG-Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1999) 55:465-475.
   PubMed Web of Science ®Google Scholar
• AKAGI Y, ISAKA Y, ARAI M et al.: Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1996) 50:148-155.
   PubMed Web of Science ®Google Scholar
• MIYAJIMA A, CHEN J, LAWRENCE C et al.: Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. (2000) 58:2301-2313.
   PubMed Web of Science ®Google Scholar
• FUKASAWA H, YAMAMOTO T, SUZUKI H et al.: Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int. (2004) 65:63-74.
   PubMed Web of Science ®Google Scholar
• ISLAM M, BURKE JF JR, MCGOWAN TA et al.: Effect of anti-transforming growth factor-β antibodies in cyclosporine-induced renal dysfunction. Kidney Int. (2001) 59:498-506.
   PubMed Web of Science ®Google Scholar
• LING H, LI X, JHA S et al.: Therapeutic role of TGF-β-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J. Am. Soc. Nephrol. (2003) 14:377-388.
   PubMed Web of Science ®Google Scholar
• SHARMA K, JIN Y, GUO J et al.: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes (1996) 45:522-530.
   PubMed Web of Science ®Google Scholar
• CHEN S, IGLESIAS-DE LA CRUZ MC, JIM B et al.: Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochem. Biophys. Res. Commun. (2003) 300:16-22.
   PubMed Web of Science ®Google Scholar
• DAHLY AJ, HOAGLAND KM, FLASCH AK et al.: Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am. J. Physiol. (2002) 283:R757-R767.
   Web of Science ®Google Scholar
• KELLY FJ, ANDERSON S, THOMPSON MM et al.: Acute and chronic renal effects of recombinant human TGF-β2 in the rat. J. Am. Soc. Nephrol. (1999) 10:1264-1273.
   PubMed Web of Science ®Google Scholar
• DAHLY-VERNON AJ, SHARMA M, MCCARTHY ET et al.: Transforming growth factor-β, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension (2005) 45:643-648.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, ZOJA C, CAMPANA M et al.: Beneficial effect of TGF-β antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp. Nephrol. (2006) 104(4):e158-e168
   PubMed Web of Science ®Google Scholar
• GRYGIELKO ET, MARTIN WM, TWEED C et al.: Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β Type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. (2005) 313:943-951.
   PubMed Web of Science ®Google Scholar
• GELLIBERT F, DE GOUVILLE AC, WOOLVEN J et al.: Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-β Type I receptor inhibitor. J. Med. Chem. (2006) 49:2210-2221.
   PubMed Web of Science ®Google Scholar
• HWANG M, KIM HJ, NOH HJ et al.: TGF-β1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp. Mol. Pathol. (2006) 81(1):48-54.
   PubMed Web of Science ®Google Scholar
• KULKARNI AB, KARLSSON S: Inflammation and TGF β 1: lessons from the TGF β 1 null mouse. Res. Immunol. (1997) 148:453-456.
   Google Scholar
• SHULL MM, ORMSBY I, KIER AB et al.: Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature (1992) 359:693-699.
   PubMed Web of Science ®Google Scholar
• KULKARNI AB, HUH CG, BECKER D et al.: Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA (1993) 90:770-774.
   PubMed Web of Science ®Google Scholar
• LAN HY, MU W, TOMITA N et al.: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J. Am. Soc. Nephrol. (2003) 14:1535-1548.
   PubMed Web of Science ®Google Scholar
• HOU CC, WANG W, HUANG XR et al.: Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-β signaling and fibrosis in rat remnant kidney. Am. J. Pathol. (2005) 166:761-771.
   PubMed Web of Science ®Google Scholar
• SATO M, MURAGAKI Y, SAIKA S et al.: Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. (2003) 112:1486-1494.
   PubMed Web of Science ®Google Scholar
• YANG J, DAI C, LIU Y: A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J. Am. Soc. Nephrol. (2005) 16:68-78.
   PubMed Web of Science ®Google Scholar
• LIU Y: Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. (2004) 287:F7-F16.
   PubMed Web of Science ®Google Scholar
• ZEISBERG M, HANAI J-I, SUGIMOTO H et al.: BMP-7 counteracts TGF-β1- induced epithelial-to-mesenchymal transition and reverses chronic renal injury Nat. Med. (2003) 7:964-969.
   Google Scholar
• KLAHR S, MORRISSEY J, HRUSKA K et al.: New approaches to delay the progression of chronic renal failure. Kidney Int. Suppl. (2002):23-26.
   PubMedGoogle Scholar
• OMATA M, TANIGUCHI H, KOYA D et al.: N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J. Am. Soc. Nephrol. (2006) 17:674-685.
   PubMed Web of Science ®Google Scholar
• AZUMA H, BANNO K, YOSHIMURA T: Pharmacological properties of N-(3’,4’-dimethoxycinnamoyl) anthranilic acid (N-5’), a new anti-atopic agent. Br. J. Pharmacol. (1976) 58:483-488.
   PubMed Web of Science ®Google Scholar
• UKAI K, MASUDA S, SHINOKI J et al.: Clinical and pathophysiological evaluation of tranilast in patients with pollinosis: the effects of pre-seasonal treatment. Auris Nasus Larynx (1993) 20:275-284.
   PubMedGoogle Scholar
• QI W, CHEN X, TWIGG S et al.: Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int. (2006) 69:989-995.
   PubMed Web of Science ®Google Scholar
• KELLY DJ, ZHANG Y, COX AJ et al.: Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int. (2006) 69:1954-1960.
   PubMed Web of Science ®Google Scholar
• WU MJ, WEN MC, CHIU YT et al.: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. (2006) 69:2029-2036.
   PubMed Web of Science ®Google Scholar
• COJOCEL C, AL-MAGHREBI M, THOMSON MS et al.: Modulation of the transforming growth factor β1 by vitamin E in early nephropathy. Med. Princ. Pract. (2005) 14:422-429.
   PubMed Web of Science ®Google Scholar
• SHIHAB FS, BENNETT WM, YI H et al.: Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am. J. Transplant. (2002) 2:111-119.
   PubMed Web of Science ®Google Scholar
• SHIMIZU T, KURODA T, HATA S et al.: Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. (1998) 54:99-109.
   PubMed Web of Science ®Google Scholar
• SHIMIZU T, FUKAGAWA M, KURODA T et al.: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int. Suppl. (1997) 63:S239-S243.
   PubMed Web of Science ®Google Scholar
• MA LJ, MARCANTONI C, LINTON MF et al.: Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. (2001) 59:1899-1910.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, EBIHARA I, TOMINO Y et al.: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. (1995) 47:481-489.
   PubMed Web of Science ®Google Scholar
• TOSTES RC, TOUYZ RM, HE G et al.: Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (2002) 39:892-900.
   Google Scholar
• ITO T, WILLIAMS JD, FRASER D et al.: Hyaluronan attenuates transforming growth factor-β1-mediated signaling in renal proximal tubular epithelial cells. Am. J. Pathol. (2004) 164:1979-1988.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA T, LAN HY, GLUSHAKOVA O et al.: Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-β1 in rat proximal tubular cells and mouse fibroblasts. J. Am. Soc. Nephrol. (2005) 16:899-904.
   PubMed Web of Science ®Google Scholar
• DANIEL C, WIEDE J, KRUTZSCH HC et al.: Thrombospondin-1 is a major activator of TGF-β in fibrotic renal disease in the rat in vivo. Kidney Int. (2004) 65:459-468.
   PubMed Web of Science ®Google Scholar
• LAVOIE P, ROBITAILLE G, AGHARAZII M et al.: Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. (2005) 23:1895-1903.
   PubMed Web of Science ®Google Scholar
• SUTHANTHIRAN M, LI B, SONG JO et al.: Transforming growth factor-β1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. USA (2000) 97:3479-3484.
   PubMed Web of Science ®Google Scholar
• CAMBIEN F, RICARD S, TROESCH A et al.: Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l’Infarctus du Myocarde (ECTIM) Study. Hypertension (1996) 28:881-887.
   PubMed Web of Science ®Google Scholar
• ZACCHIGNA L, VECCHIONE C, NOTTE A et al.: Emilin1 links TGF-β maturation to blood pressure homeostasis. Cell (2006) 124:929-942.
   PubMed Web of Science ®Google Scholar
• KURIHARA H, YOSHIZUMI M, SUGIYAMA T et al.: Transforming growth factor-β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem. Biophys. Res. Commun. (1989) 159:1435-1440.
   PubMed Web of Science ®Google Scholar
• GABRIEL A, KUDDUS RH, RAO AS et al.: Down-regulation of endothelin receptors by transforming growth factor β1 in hepatic stellate cells. J. Hepatol. (1999) 30:440-450.
   PubMed Web of Science ®Google Scholar
• KAKOKI M, HIRATA Y, HAYAKAWA H et al.: Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation (1999) 99:1242-1248.
   PubMed Web of Science ®Google Scholar
• HIRATA Y, EMORI T, EGUCHI S et al.: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. (1993) 91:1367-1373.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Randomized placebo-controlled trial effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (1997) 349:1857-1863.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, ZAGROBELNY J: Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney Int. Suppl. (2003):S77-S85.
   Google Scholar
• RUGGENENTI P, FASSI A, ILIEVA AP et al.: Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. (2004) 351:1941-1951.
   PubMed Web of Science ®Google Scholar
• PRAGA M, ANDRADE CF, LUNO J et al.: Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol. Dial. Transplant. (2003) 18:1806-1813.
   PubMed Web of Science ®Google Scholar
• SONG JH, LEE SW, SUH JH et al.: The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-β excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin. Nephrol. (2003) 60:318-326.
   PubMed Web of Science ®Google Scholar
• FIORETTO P, STEFFES MW, SUTHERLAND DE et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. (1998) 339:69-75.
   PubMed Web of Science ®Google Scholar
• MAUER SM, STEFFES MW, SUTHERLAND DE et al.: Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes (1975) 24:280-285.
   PubMed Web of Science ®Google Scholar
• MA LJ, NAKAMURA S, WHITSITT JS et al.: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int. (2000) 58:2425-2436.
   PubMed Web of Science ®Google Scholar
• REMUZZI A, GAGLIARDINI E, SANGALLI F et al.: ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. (2006) 69:1124-1130.
   PubMed Web of Science ®Google Scholar
• REMUZZI A, GAGLIARDINI E, DONADONI C et al.: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int. (2002) 62:885-894.
   PubMed Web of Science ®Google Scholar
• LIU BC, ZHANG L, LV LL et al.: Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am. J. Nephrol. (2006) 26:483-490.
   PubMed Web of Science ®Google Scholar
• ARATA S, OHMI A, MIZUKOSHI F et al.: Urinary transforming growth factor-β1 in feline chronic renal failure. J. Vet. Med. Sci. (2005) 67:1253-1255.
   PubMed Web of Science ®Google Scholar
• GOUMENOS DS, KALLIAKMANI P, TSAKAS S et al.: Urinary transforming growth factor-β1 as a marker of response to immunosuppressive treatment, in patients with crescentic nephritis. BMC Nephrol. (2005) 6:16.
   PubMedGoogle Scholar